Safety of sulfamethoxazole–trimethoprim for the treatment of bacterial infection in outpatient settings: A systematic review and meta‐analysis with active comparator disproportionality analysis
British Journal of Clinical Pharmacology · 2025
DOI: 10.1002/bcp.70051 ↗Kurz gefasst
Metaanalyse in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Rebecca Preyra und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Pharmacology, Western University, London, Ontario, Canada. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Bacterial Infections, Trimethoprim, Sulfamethoxazole Drug Combination. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aims
Sulfamethoxazole–trimethoprim (SMX‐TMP) is a widely used antibiotic for treating bacterial infections, but its safety in adult outpatients remains understudied. This systematic review and meta‐analysis evaluated the safety profile of SMX‐TMP and identified critical research gaps. The pharmacovigilance study aimed to validate and extend findings from meta‐analyses to better understand the real‐world safety of SMX‐TMP.
Methods
We searched MEDLINE and Embase up to 12 August 2024, to identify studies comparing adverse drug events (ADEs) following SMX‐TMP vs . other antibiotics in adult outpatients. Meta‐analyses were performed where data allowed. A pharmacovigilance study using the Food and Drug Administration Adverse Event Reporting System was conducted to supplement our findings.
Results
Our review, which included 43 studies, found SMX‐TMP had a nearly 3‐fold higher risk of rash compared to other antibiotics (pooled risk ratio 2.56, 95% confidence interval [1.69, 3.89], I 2 = 0%, n = 4458 participants, 24 randomized control trials). Pharmacovigilance data confirmed a higher frequencies of skin disorders and other ADEs compared to various comparator drugs. Compared to azithromycin, SMX‐TMP was associated with a 5‐fold increase in Stevens–Johnson syndrome, a 3‐fold increase in toxic epidermal necrolysis, and a 10‐fold increase in drug reaction with eosinophilia and systemic symptoms. Additionally, SMX‐TMP showed a 10‐fold increase in reports of pancytopenia, a 6‐fold increase in neutropenia, a 4‐fold increase in both thrombocytopenia and aplastic anaemia, a 56‐fold increase in hyperkalaemia, and a 10‐fold increase in hyponatraemia.
Conclusion
Our meta‐analyses and pharmacovigilance study suggested SMX‐TMP was associated with increased risk of ADEs compared to other antibiotics including amoxicillin/clavulanate, azithromycin and nitrofurantoin. Further robust research is essential to confirm these safety signals and guide clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology and Pharmacology, Western University, London, Ontario, Canada.
- ICES Western, London, ON, Canada.
- Department of Epidemiology & Biostatistics, Western University, London, ON, Canada.
- Lawson Health Research Institute, London Health Sciences Centre, London, Ontario, Canada.
ORCID-Profile: Flory T Muanda
Zitieren
APA
Preyra, R., Eddin, L. E., Ahmadi, F., Jafari, A., & Muanda, F. T. (2025). Safety of sulfamethoxazole–trimethoprim for the treatment of bacterial infection in outpatient settings: A systematic review and meta‐analysis with active comparator disproportionality analysis. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70051
Vancouver
Preyra R, Eddin LE, Ahmadi F, Jafari A, Muanda FT. Safety of sulfamethoxazole–trimethoprim for the treatment of bacterial infection in outpatient settings: A systematic review and meta‐analysis with active comparator disproportionality analysis. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70051
BibTeX
@article{Preyra2025,
author = {Preyra, Rebecca and Eddin, Lujain Ez and Ahmadi, Fatemeh and Jafari, Atefeh and Muanda, Flory T},
title = {Safety of sulfamethoxazole–trimethoprim for the treatment of bacterial infection in outpatient settings: A systematic review and meta‐analysis with active comparator disproportionality analysis},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/bcp.70051}
}
EUVIMED